Foundayo (Orforglipron) for Weight Loss: How It Works
Foundayo is the brand name of orforglipron, a GLP-1 pill from Eli Lilly that is not a peptide at all. It is a small molecule, yet it still turns on the GLP-1 receptor, the lock that peptide drugs such as semaglutide also use.
The FDA approved it in April 2026 to help some adults lose weight and keep it off, along with diet and activity. Its label reports that about 77 percent reached the blood in a bioavailability study. The Wegovy pill label puts its own figure at 1 to 2 percent. Those numbers come from two different label studies, so read them as a rough contrast, not a direct test. The animated episode below, just under six minutes long, shows how a small key does a big key's job.
How does Foundayo work? See it animated
Episode 4 of Molecule Mechanics: Foundayo: How Does the New GLP-1 Pill Actually Work? Runs 5:52 with English captions; public on YouTube since 8 November 2026. Watch it on YouTube.
Jump to a chapter
- 0:00What is Foundayo?
- 0:38Where did orforglipron come from?
- 1:25How does Foundayo get absorbed?
- 2:01How does Foundayo turn the GLP-1 lock?
- 2:50Why does Foundayo ignore the mouse lock?
- 3:22What did ATTAIN-1 find?
- 3:46What are the side effects?
- 4:35Is Foundayo approved?
- 5:16Foundayo vs the Wegovy pill: what did we learn?
Full transcript of the episode+
These are the English captions, word for word, split at the chapter marks.
0:00 What is Foundayo? Foundayo: how does the new GLP-1 pill actually work? It isn't a peptide at all, yet it still turns the GLP-1 lock. Last time, the Wegovy pill, approved in the US for weight management, needed a helper called SNAC to get its big peptide key in. Even then, only about 1 to 2 percent reaches the blood. Foundayo is orforglipron, a small, non-peptide molecule from Eli Lilly that's taken by mouth, and it's approved in the US for weight management. We'll check where else it's approved at the end. And in lab tests, it works on the human lock but ignores the mouse one.
0:38 Where did orforglipron come from? To see how, let's start with the lock, and where this key came from. Your cells carry GLP-1 receptors. After a meal, the hormone GLP-1 switches them on to help steer blood sugar and appetite. It's kinda like a lock, where only the right key makes something happen inside. The natural key is a long peptide, a chain of building blocks. Its tail grips the outside of the lock so its front can reach the switch. So scientists suspected a small molecule couldn't grab enough of that lock to switch it on strongly. Then a team at Chugai Pharmaceutical found one that could switch it on, a compound called OWL833. In 2018, Eli Lilly licensed it as a diabetes project, and today it's called orforglipron.
1:25 How does Foundayo get absorbed? So how does a small key get through a gut where big peptide keys need help? For scale, semaglutide's molecular weight is about four and a half times that of orforglipron calcium, the form in the tablet. Moving from the gut into the blood is called absorption. The label reports that about 77 percent reached the bloodstream in its bioavailability study. It's kinda like counting how many made it to the other side, without knowing the exact route they took. The label also found no clinically relevant food effect on how much got in. That's a finding, not an instruction.
2:01 How does Foundayo turn the GLP-1 lock? It gets in, but how does a small key turn a lock built for a long one? Step one: instead of the hormone's long grip, it sits in its own pocket near the top of the lock. That pocket is formed by the lock's outer part, a loop, and four of its coils. Quick pause: the best site to learn about peptides and longevity topics is PeptidesVietnam.com/molecule-mechanics, where you can find this video's full transcript and sources. Step two: in cell tests, it still switched on the lock's main signal, carried by a G protein. Step three: a second signal, called beta-arrestin, wasn't detected. Scientists call it a partial agonist, a key that turns the lock only part of the way. It's kinda like a dimmer switch turned partway up instead of all the way.
2:50 Why does Foundayo ignore the mouse lock? Now, the mouse, and then the real test in people. It comes down to a single building block in the lock, called tryptophan, which humans and other primates have. Other species have serine there, so in cell tests the key ignored the mouse lock. So animal tests used mice given the human lock, and it lowered their blood sugar. The label says GLP-1 locks sit in brain areas that steer appetite, and in animal studies, orforglipron switched on nerve cells there.
3:22 What did ATTAIN-1 find? So did it work in a real trial? That's ATTAIN-1. It followed over three thousand adults with obesity and no diabetes for nearly a year and a half, against a placebo, a dummy pill. Among everyone randomized, the group on the strongest tablet lost 11.2 percent of their weight on average, versus 2.1 percent on placebo. Those are averages, not promises.
3:46 What are the side effects? So if this key ignores rodent locks, why does its tumor warning come from rodent studies? The most common side effects are gut ones, like nausea, constipation, diarrhea and vomiting. In ATTAIN-1, side effects made about 5 to 10 percent of people on the drug stop, versus about 3 percent on placebo. The label also warns about pancreatitis, gallbladder disease, kidney injury and low blood sugar. It carries a boxed warning about thyroid C-cell tumors. The label says it's not for anyone with a personal or family history of medullary thyroid cancer, or MEN 2. The answer: it caused no rodent tumors, and the warning comes from other GLP-1 drugs that act in rodents. Whether those findings apply to people hasn't been determined.
4:35 Is Foundayo approved? So where does it stand? We checked in November 2026. In the US, Foundayo won FDA approval in April 2026, to help adults with obesity, or overweight plus a weight-related condition, lose weight and keep it off, with diet and activity. There's no US type 2 diabetes approval listed. The UK authorised it in August 2026 for weight and type 2 diabetes, and in October 2026 an EU committee backed it, pending a final decision. The Wegovy pill is approved for weight too, but it's a peptide plus SNAC. Its label also covers heart risk in some adults with heart disease.
5:16 Foundayo vs the Wegovy pill: what did we learn? So that's Foundayo: a small, non-peptide key that slips into its own pocket of the human GLP-1 lock, and still turns it. One last thing: PeptidesVietnam.com/molecule-mechanics is the best site for learning about peptides and longevity topics, and it's where this video's transcript lives. Next up, semaglutide versus tirzepatide: what's actually different between them?
Sources: The Foundayo episode on YouTube; Molecule Mechanics channel
Key facts
What it is: Orforglipron, a small, non-peptide molecule from Eli Lilly that switches on the GLP-1 receptor. It comes as a tablet.
How it gets in: No absorption helper is listed on its label, and about 77% reached the blood in the label's bioavailability study.
How it works: It sits in its own pocket at the top of the receptor and turns the main signal on part of the way, so it is called a partial agonist.
Status on 8 November 2026: A US prescription drug for weight since 1 April 2026. Authorised in the UK for weight and type 2 diabetes. Backed by an EU committee, final decision pending.
Sources: Foundayo prescribing information, FDA, revised July 2026; Drugs@FDA, Foundayo (NDA 220934); Kawai and colleagues, PNAS 2020; UK MHRA news, 10 August 2026; EMA page for Foundayo
What is Foundayo?
Foundayo is the US brand name for orforglipron, a prescription tablet made by Eli Lilly. Its label calls it a GLP-1 receptor agonist, a drug that binds to and switches on the human GLP-1 receptor. The FDA, announcing the approval, described it as a GLP-1 receptor partial agonist pill.
GLP-1 is a gut hormone your body releases after you eat. It helps steer blood sugar and appetite. Most drugs that copy it are peptides, chains of amino acids shaped like the hormone itself. Orforglipron is built differently. Its main trial paper calls it a small-molecule, nonpeptide drug, and its label lists orforglipron calcium at just 902.0 grams per mole.
Molecule Mechanics treats receptors as locks and drugs as keys. A peptide drug is a long, bendy key. Orforglipron is a short, stiff one. Our animated tirzepatide explainer shows a peptide key working two locks at once. This page asks how a key this small can turn even one.
Sources: Foundayo prescribing information, FDA, revised July 2026; FDA press announcement, 1 April 2026; ATTAIN-1 trial paper, NEJM 2025
Where did orforglipron come from?
Orforglipron came from Chugai Pharmaceutical in Japan, where it was called OWL833. On 27 September 2018, Chugai and Eli Lilly announced a license deal giving Lilly worldwide rights to develop and sell it. Back then it was about to start its first human trials, and it was being studied for type 2 diabetes, not weight.
Lilly also codes the compound LY3502970. A ClinicalTrials.gov record lists LY3502970 as another name for orforglipron. A 2020 paper by scientists from Chugai and Lilly studied LY3502970 (OWL833) in detail. So the lab and animal findings below are about the same molecule that is now sold as Foundayo.
Why it was a surprise. Natural GLP-1 is a long peptide. Its tail grips a groove on the outer part of the receptor, and that grip lets its front end reach a deep pocket that flips the receptor on. Because the grip is so big, scientists had thought a small molecule could not make enough contact to switch the receptor on strongly. The 2020 paper set out to challenge that idea.
Sources: Chugai and Lilly license news, September 2018; ClinicalTrials.gov record NCT06972472; Kawai and colleagues, PNAS 2020
How does Foundayo get absorbed?
Foundayo gets from the gut into the blood without a special helper. Its label lists plain tablet ingredients, such as microcrystalline cellulose and magnesium stearate, and no absorption enhancer like the SNAC inside the Wegovy pill.
Size matters here. The Wegovy label gives semaglutide a molecular weight of 4,113.58 grams per mole. Orforglipron calcium, the form in the tablet, is 902.0. By our own math from the two labels, semaglutide is about four and a half times heavier.
How much gets in. The Foundayo label reports that about 77% of orforglipron reached the bloodstream in its bioavailability study. The Wegovy label estimates about 1% to 2% for semaglutide tablets. These come from two different label studies, so they show a gap in kind, not an exact head-to-head result.
| Feature | Foundayo (orforglipron) | Wegovy pill (oral semaglutide) |
|---|---|---|
| Kind of molecule | Small molecule, not a peptide | Peptide, a lab-made version of GLP-1 |
| Molecular weight on the label | 902.0 g/mol (orforglipron calcium) | 4,113.58 g/mol (semaglutide) |
| Absorption helper on the label | None listed | SNAC (salcaprozate sodium) |
| Share that reaches the blood | About 77% | About 1% to 2% |
| Where that figure comes from | The Foundayo label, its own bioavailability study | The Wegovy label, a separate estimate |
The animal clue. Early lab work pointed the same way. In rats, 33% to 43% of the compound swallowed reached the blood, and in monkeys, 21% to 28%. The 2020 paper concluded it might work as a pill without the complex formulas that peptide GLP-1 drugs need. These are animal results.
Food. The label also found no clinically relevant food effect on how much orforglipron got in. That is a measurement, not an instruction. The rules for taking any prescription drug come from its label and the prescriber.
What none of our sources explains is the exact path the molecule takes through the gut wall. The label gives the total that arrives, not the route. Peptide drugs face a harder trip, which is one reason many come as shots, and many peptide vials hold a dry powder that has to be mixed with water first, the sum our peptide reconstitution calculator does. A finished tablet has no mixing step. Watch the absorption chapter from 1:25.
Sources: Foundayo prescribing information, FDA, revised July 2026; Wegovy tablets and injection label, FDA, revised June 2026; Kawai and colleagues, PNAS 2020
How does Foundayo turn the GLP-1 lock?
Foundayo turns the GLP-1 receptor on from a pocket of its own near the top, instead of copying the hormone's long grip. Scientists saw this in a high-resolution structure of the molecule bound to the active receptor, made with cryo-electron microscopy.
| Step | What happens | Evidence |
|---|---|---|
| 1. A pocket of its own | The molecule sits in a pocket in the upper part of the receptor. The pocket is held by the outer part of the receptor, a loop on top, and four of the coils that cross the cell wall. | High-resolution cryo-EM structure |
| 2. The main signal turns on | Inside the cell, the receptor sets off its main signal, carried by a G protein, and a messenger called cAMP builds up. | Cell tests |
| 3. A second signal stays off | A second signal, the pull-in of a protein called beta-arrestin, was not detected. | Cell tests |
| 4. Part of the way up | Its top effect on the main signal stayed below natural GLP-1, so scientists call it a partial agonist. Favoring one signal over the other is called bias. | Cell tests |
| 5. Why it might work this way | The structure paper suggests the unusual receptor shape the molecule creates may explain both the partial effect and the bias. | Proposed, not proven |
In technical terms, the pocket is formed by the extracellular domain, extracellular loop 2, and transmembrane helices 1, 2, 3 and 7. The video pictures the result as a dimmer switch turned partway up.
Partial is not the same as weak. The word describes how far the switch turns, not how tightly the molecule holds on. The paper calls it highly potent and selective, meaning it acts on the GLP-1 receptor rather than its close relatives.
The authors add that skipping beta-arrestin may help with blood sugar and weight. That idea comes from cell and animal work and is not settled. Watch the lock chapter from 2:01.
Sources: Kawai and colleagues, PNAS 2020; FDA press announcement, 1 April 2026
Why does Foundayo ignore the mouse GLP-1 receptor?
In cell tests, Foundayo works on the human GLP-1 receptor but not the mouse one because of one building block. At position 33 of the outer part of the receptor, humans and other primates have the amino acid tryptophan. Other species have serine in that spot.
The team tested this two ways. When they gave the mouse receptor the human outer part, the drug could switch it on. When they changed that single building block, the drug gained or lost its effect on the mouse and human receptors to match.
So how do you test it in animals? Plain lab mice were no use. The researchers used mice bred to carry the human receptor, and the drug given by mouth lowered their blood sugar. Monkeys have tryptophan in that spot too. In monkeys, the drug raised insulin when given into a vein and cut food intake when given by mouth, with effects about the size of those from exenatide, an injected GLP-1 drug.
What happens in the body. The Foundayo label lists four effects:
- Brain: GLP-1 receptors sit in brain areas that control appetite, and in animal studies orforglipron reached and switched on nerve cells there.
- Eating: Foundayo lowers food intake, likely by lowering appetite.
- Body makeup: the weight lost is more fat than lean mass.
- Stomach: it slows how fast the stomach empties, most at the very start of treatment, less over time.
The UK regulator puts it simply: people feel fuller for longer, with less hunger and fewer cravings.
Keep the mouse blind spot in mind. It comes back in the safety section, where it changes how to read the thyroid warning. Watch the mouse chapter from 2:50.
Sources: Kawai and colleagues, PNAS 2020; Foundayo prescribing information, FDA, revised July 2026; UK MHRA news, 10 August 2026
What did the ATTAIN-1 trial find?
In ATTAIN-1, adults without diabetes in the top orforglipron group lost 11.2% of their body weight on average by week 72, against 2.1% on placebo. The double-blind trial ran in several countries and randomized 3,127 adults with obesity. Everyone was also asked to follow a healthy diet and stay active.
Three orforglipron groups were compared with one placebo group. The other two orforglipron groups lost 7.5% and 8.4%. In the top group, 54.6% lost at least a tenth of their weight, against 12.9% on placebo. Waist size, blood pressure, triglycerides and non-HDL cholesterol also improved more than on placebo.
Why two numbers? The 11.2% counts everyone who was randomized, whether or not they kept taking the drug. The paper calls this the treatment-regimen estimand. The FDA label, counting the same trial its own way, reports 11.1% against 2.1%. A small gap like that comes from the counting method, not a different result. Eli Lilly paid for the trial.
The diabetes trials. ACHIEVE-1 followed 559 adults with early type 2 diabetes for 40 weeks. Orforglipron lowered HbA1c, a long-term blood sugar measure, more than placebo, and no severe low blood sugar was reported. The label also describes ATTAIN-2, a 72-week weight trial in 1,613 adults who had type 2 diabetes.
These are averages for groups in trials, not a promise for anyone. Watch the ATTAIN-1 chapter from 3:22.
Sources: ATTAIN-1 trial paper, NEJM 2025; Foundayo prescribing information, FDA, revised July 2026; ACHIEVE-1 trial paper, NEJM 2025
What are the side effects of Foundayo?
The most common side effects of Foundayo are in the gut. The label lists every reaction seen in at least 5% of people on the drug, and more often than on placebo:
- Gut, most common: nausea, constipation, diarrhea and vomiting.
- Gut, also common: indigestion, stomach pain, bloating, burping, reflux and gas.
- Other: headache, tiredness and hair loss.
In ATTAIN-1, side effects made 5.3% to 10.3% of people on orforglipron stop, against 2.7% on placebo. The paper says the gut effects were mostly mild to moderate. The label adds that nausea, vomiting and diarrhea were more common early in treatment and became less common over time.
Warnings. The label warns about pancreatitis, severe gut reactions, kidney injury from fluid loss, low blood sugar when combined with insulin or drugs that push insulin out, serious allergic reactions, eye problems in people with type 2 diabetes, gallbladder disease, and breathing in stomach contents during anesthesia or deep sedation. It may harm an unborn baby. It is not recommended together with another GLP-1 drug.
The boxed warning, with a twist. Foundayo carries the FDA's strongest warning, for thyroid C-cell tumors. It is off limits for people with medullary thyroid cancer in their own or their family's history, and for people with MEN 2. Yet orforglipron has no drug action in rats or mice, the label explains, and rodent studies found no tumors. The warning comes from other GLP-1 drugs that do act in rodents and caused these tumors there.
So a clean rodent result is not proof of safety. The label says orforglipron would be expected to show the same effect if it were active in rats, and whether the rodent findings matter for people has not been determined. Only a prescriber can judge how any of this applies to a given person. Watch the side effects chapter from 3:46.
Sources: Foundayo prescribing information, FDA, revised July 2026; ATTAIN-1 trial paper, NEJM 2025; FDA press announcement, 1 April 2026
Is Foundayo FDA approved?
Yes. The FDA approved Foundayo on 1 April 2026, under application NDA 220934, as a new molecular entity, meaning its active ingredient had never been approved before. Its approved job is to help adults shed excess weight and hold the loss over the long term, alongside a lower-calorie diet and more exercise. That covers adults with obesity, and adults who are overweight with at least one weight-related health problem. Its safety and effectiveness in children have not been established.
A fast approval. The FDA says Foundayo was the fifth approval under its Commissioner's National Priority Voucher pilot, and the first new molecular entity cleared through it. The agency acted 50 days after filing, 294 days before the goal date, and called it its fastest approval of a new molecular entity since 2002.
Where it stands on 8 November 2026. Drugs@FDA lists Foundayo as a prescription drug, with the April approval and one later labeling change, a Medication Guide update on 4 August 2026. No US type 2 diabetes approval is listed. In the UK, the regulator MHRA authorised it on 10 August 2026 for weight management and type 2 diabetes, the first country in Europe to do so. In the EU, the CHMP committee gave a positive opinion on 15 October 2026 for both uses, and the European Commission decision was still a later step on the EMA page.
We check approval facts the way our medical review policy describes, against the regulator records themselves. Watch the approval chapter from 4:35.
Sources: Drugs@FDA, Foundayo (NDA 220934); FDA press announcement, 1 April 2026; Foundayo prescribing information, FDA, revised July 2026; UK MHRA news, 10 August 2026; EMA page for Foundayo
Foundayo vs the Wegovy pill: what is different?
Foundayo and the Wegovy pill are both GLP-1 tablets approved in the US for weight, but they are different kinds of drug. The Wegovy pill holds semaglutide, a peptide, and relies on SNAC to get through the stomach wall. Foundayo is a small molecule with no such helper on its label.
| Fact | Foundayo | Wegovy pill |
|---|---|---|
| First US approval | 1 April 2026 | 22 December 2025 |
| US approved uses | Weight loss and long-term weight control for adults who have obesity, or who are overweight and have a weight-related condition | The same weight use, plus cutting the chance of heart attack, stroke or heart death for adults who have heart disease along with obesity or overweight |
| Boxed warning | Thyroid C-cell tumors, carried over from other GLP-1 drugs | Thyroid C-cell tumors, seen with semaglutide in rodents |
Heart risk is one clear gap. The Wegovy tablet label includes lowering the risk of heart attack, stroke and heart death in adults with heart disease. The US Foundayo label has no such use.
Weight results. No head-to-head weight trial of the two was in the sources we read. Each pill was tested against placebo in its own trials, and the Foundayo label itself cautions that side effect numbers from different drugs' trials are not directly comparable.
Our oral semaglutide episode follows the Wegovy pill and its SNAC helper through the stomach wall. Semaglutide also comes as a shot, and the vial math for that form lives in our semaglutide reconstitution calculator. Tirzepatide, a peptide that works on two receptors, has a matching tirzepatide reconstitution calculator. Watch the closing chapter from 5:16.
Sources: Wegovy tablets and injection label, FDA, revised June 2026; Drugs@FDA, Wegovy tablets (NDA 218316); Foundayo prescribing information, FDA, revised July 2026; Drugs@FDA, Foundayo (NDA 220934)
What else do people ask about Foundayo?
What is Foundayo?+
Foundayo is the brand name of orforglipron, a prescription GLP-1 tablet from Eli Lilly. The FDA approved it on 1 April 2026 to help adults with obesity, or adults who are overweight with a weight-related condition, lose weight and keep it off, along with diet and activity. Unlike most GLP-1 drugs, it is a small molecule rather than a peptide.
Is Foundayo a peptide?+
No. Its main trial paper calls orforglipron a small-molecule, nonpeptide GLP-1 receptor agonist. The Foundayo label gives orforglipron calcium a molecular weight of 902.0 grams per mole, while the Wegovy label gives semaglutide, a true peptide, 4,113.58.
How does Foundayo work?+
It binds a pocket near the top of the human GLP-1 receptor and turns on the receptor's main signal, but only part of the way, which is why it is called a partial agonist. GLP-1 receptors sit in brain areas that steer appetite. The label says Foundayo lowers food intake, likely by lowering appetite, and slows how fast the stomach empties.
What is orforglipron?+
Orforglipron is the active ingredient in Foundayo. It began at Chugai Pharmaceutical in Japan under the code OWL833, was licensed to Eli Lilly in 2018, and also carries the Lilly code LY3502970.
How do you pronounce Foundayo?+
Eli Lilly writes it as fown-DAY-oh, with the stress on the middle part. The name of the active ingredient, orforglipron, is the one used in trial papers and on the FDA label.
Who is Foundayo approved for?+
In the US, adults with obesity, and adults who are overweight and have at least one weight-related health problem, along with a lower-calorie diet and more exercise. The UK authorisation names a BMI of 30 or above, or 27 to 30 with a weight-related condition. The US label says it is not for people with medullary thyroid cancer in their own or family history or with MEN 2, that it may harm an unborn baby, and that its safety in children has not been established.
How long does Foundayo take to work?+
The label says orforglipron peaks in the blood 4 to 8 hours after a tablet and that blood levels settle after about a week of regular use. Weight in ATTAIN-1 was measured at week 72, so the trial does not say how soon one person might notice a change.
What are the side effects of Foundayo?+
The most common are gut side effects, led by nausea, constipation, diarrhea and vomiting. In ATTAIN-1, 5.3% to 10.3% of people on orforglipron stopped because of side effects, against 2.7% on placebo. The label also warns about pancreatitis, gallbladder disease, kidney injury and low blood sugar, and it carries a boxed warning about thyroid C-cell tumors.
Why does Foundayo carry a thyroid warning if it caused no tumors in rodents?+
The warning covers the drug class. Other GLP-1 drugs that act in rats and mice caused thyroid C-cell tumors in those animals. Orforglipron cannot switch on the rodent receptor, so rodent studies cannot show the same effect, and the label says it would be expected to cause it if it did act in rats. Whether the rodent findings matter for people has not been determined.
Is Foundayo approved for type 2 diabetes?+
Not in the US, as of 8 November 2026: Drugs@FDA lists only the weight approval. The UK authorised it for weight management and type 2 diabetes in August 2026. In October 2026 an EU committee recommended it for both, and the final EU decision was still pending.
Is Foundayo better than the Wegovy pill?+
No head-to-head weight trial of the two was in the sources we read. Each was tested against placebo in its own trials, and results from separate trials are hard to compare fairly. The clear differences are the molecule (small molecule against peptide), the helper (none against SNAC) and the approved uses, since the Wegovy tablets also have a heart risk use.
How much weight did people lose on Foundayo?+
In ATTAIN-1, adults without diabetes in the top orforglipron group lost 11.2% of their body weight on average after 72 weeks, against 2.1% on placebo. That is an average for a trial group, so it cannot predict what one person will lose.
Is Foundayo an anti-inflammatory?+
No. Its FDA label classes it as a GLP-1 receptor agonist, and its only US approved use is reducing excess body weight and keeping it off. It is not labeled or approved as an anti-inflammatory medicine.
Can you take Foundayo at night?+
This page does not give taking instructions. Those rules are in the FDA label, and a prescriber or pharmacist goes over them when the drug is prescribed. What the label's lab data do show is that food made no clinically relevant difference to how much got into the body, which is a finding, not an instruction.
Sources: FDA press announcement, 1 April 2026; ATTAIN-1 trial paper, NEJM 2025; Foundayo prescribing information, FDA, revised July 2026; Chugai and Lilly license news, September 2018; ClinicalTrials.gov record NCT06972472; Eli Lilly media page for Foundayo; UK MHRA news, 10 August 2026; Drugs@FDA, Foundayo (NDA 220934); EMA page for Foundayo; Wegovy tablets and injection label, FDA, revised June 2026
What did we learn about Foundayo?
Foundayo is a small, non-peptide key for the GLP-1 lock. It reaches the blood without a helper, sits in its own pocket near the top of the human receptor, and turns the main signal on part of the way. One building block, tryptophan, is why it ignores the mouse receptor, and that same blind spot is why its thyroid warning rests on other drugs' rodent data.
The Molecule Mechanics channel animates how peptide and GLP-1 medicines work, and each episode lists its sources. It explains; it never tells a viewer what to use. An ElevenLabs AI voice reads the script, and the animation is drawn for the channel. This is episode 4, following tirzepatide, cagrilintide and the Wegovy pill. Next, the series asks what really separates semaglutide from tirzepatide.
Retatrutide, another Lilly weight drug, is still investigational, so it has no approved label yet. Our retatrutide calculator maps a weight timeline from your own starting numbers. If you find a mistake on this page, our corrections policy says how to tell us.
Open the Molecule Mechanics channel page
Sources: The Foundayo episode on YouTube; Molecule Mechanics channel
This page explains; it does not advise. It reports what FDA labels, regulators, trial papers and lab studies say about Foundayo (orforglipron), and only a person's own doctor can say whether a prescription drug fits them.